Automate Your Wheel Strategy on JSPR
With Tiblio's Option Bot, you can configure your own wheel strategy including JSPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JSPR
- Rev/Share 0.0805
- Book/Share 2.8964
- PB 1.1083
- Debt/Equity 0.0613
- CurrentRatio 4.3112
- ROIC -1.793
- MktCap 48220941.0
- FreeCF/Share -4.8156
- PFCF -0.6866
- PE 3.4104
- Debt/Assets 0.045
- DivYield 0
- ROE 0.1907
- Rating A+
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JSPR | BMO Capital Markets | Outperform | Market Perform | -- | $4 | July 8, 2025 |
| Downgrade | JSPR | RBC Capital Mkts | Outperform | Sector Perform | -- | $5 | July 8, 2025 |
| Downgrade | JSPR | William Blair | Outperform | Market Perform | -- | -- | July 7, 2025 |
| Downgrade | JSPR | Cantor Fitzgerald | Overweight | Neutral | -- | -- | July 7, 2025 |
| Initiation | JSPR | UBS | -- | Buy | -- | $38 | Feb. 13, 2025 |
| Initiation | JSPR | BMO Capital Markets | -- | Outperform | -- | $63 | Dec. 6, 2024 |
| Initiation | JSPR | JMP Securities | -- | Mkt Outperform | -- | $70 | Sept. 9, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Read More
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom. Jasper will present initial clinical data from patients enrolled in the 180mg cohort of the SPOTLIGHT Phase 1b/2a study evaluating briquilimab in subcutaneous briquilimab in …
Read More
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2024 and provided a corporate update.
Read More
About Jasper Therapeutics, Inc. (JSPR)
- IPO Date 2020-01-10
- Website https://jaspertherapeutics.com
- Industry Biotechnology
- CEO Ronald A. Martell
- Employees 64